Sunshine Biopharma Inc. (SBFM) Form 424B4 — Oct 9, 2026
Sunshine Biopharma (Nasdaq: SBFM) priced a best-efforts offering of up to 10,509,082 common units at $0.55 per unit on October 9, 2026, each unit comprising one share and two Series D warrants exercisable at $0.66 for five years, seeking gross proceeds of up to ~$6 million with estimated net proceeds of ~$5.2 million. The offering is highly dilutive: shares outstanding jump from 4,310,301 to 15,219,383, and full exercise of the Series D and pre-funded warrants could add up to roughly 65 million more shares, dwarfing the current share count. There is no minimum offering amount, so proceeds may be substantially less than the maximum.
Key figures
- Total Debt
- 6094899
- Cash Position
- 13748301
- Gross Proceeds
- 5999995.1
- Offering Price
- 0.55
- Shares Offered
- 10509082
- Shares Outstanding
- 15219383
- Net Proceeds
- $5.2 million
- Last Sale Price
- $0.34 on October 9, 2026
- Prefunded Units
- 400000
- Series DWarrants
- 21818164
- Placement Agent Fee
- 7% of gross proceeds plus 1% non-accountable expense allowance
- Series DExercise Price
- $0.66
- Reverse Split Authorization
- up to 1-for-20, effective October 19, 2026
- Shares Outstanding Before Offering
- 4310301
- Shares Underlying Series DWarrants
- 43636328
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.